Adastra Holdings Ltd.

Equities

XTRX

CA00654D1006

Pharmaceuticals

Market Closed - Canadian Securities Exchange 03:52:44 2024-04-18 pm EDT 5-day change 1st Jan Change
0.24 CAD +4.35% Intraday chart for Adastra Holdings Ltd. 0.00% +9.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Adastra Holdings Ltd. Announces Appointment of Lachlan Mcleod as Interim Chief Executive Officer CI
Adastra Holdings Ltd. Announces Resignation of Smoke Wallin from Its Board of Directors CI
Adastra Holdings Announces Executive Changes CI
Adastra Holdings Ltd. Appoints Andrew Hale, MBA, BSAE, PMP to its Board of Directors CI
Adastra Holdings Ltd. Announces Record Total Purchase Orders Received in January and February CI
Adastra Holdings Ltd. Announces Resignation of Michael Forbes as Director and Corporate Secretary, Effective March 29, 2024 CI
Adastra Holdings Ltd. Announces Resignation of Michael Forbes as CEO, Effective March 29, 2024 CI
Adastra Holdings Ltd. Receives Purchase Order from the Alberta Gaming, Liquor & Cannabis CI
Adastra Holdings Brief: Announcing it has received a Purchase Order for C$1,047,439 from Alberta Gaming, Liquor & Cannabis MT
XORTX Therapeutics Brief: Says Submitted a New Patent for the Treatment of Chronic Kidney Disease MT
Adastra Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Adastra Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
XORTX Therapeutics Announces PKD Presentation MT
Adastra Holdings Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Adastra Holdings Ltd. Auditor Raises 'Going Concern' Doubt CI
Adastra Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Adastra Brief: Engageing Hybrid Brand Management to expand sales coverage and product sell-through in BC, AB, SK, MB and ON MT
Adastra Brief: Reporting 152% increase in shipment volume for the first two months of 2023 over the monthly average shipments of 2022 MT
Adastra Brief: Citing Record shipment volume of 379,343 grams and 1,300+ orders during January and February 2023 MT
Adastra Brief: Says To Defend Lawsuit Alleging Co "Misstated Certain Material Facts"; Currently, No Specific Amount of Damages Is Claimed" MT
Adastra Labs "Clarifies and Retracts" Certain Disclosure Related to its Receipt of Health Canada Approval for Amendment to Include Cocaine Under its Controlled Substances Licence MT
Adastra Labs Receives Health Canada OK for Amendment to Include Cocaine Under its Controlled Substances Dealer's License MT
Adastra Labs Receives Health Canada Approval for the Amendment to Include Cocaine Under its Controlled Substances Dealer’s License CI
Adastra Completes Transaction to Terminate Legacy Supply Agreement, Bringing Phyto Extractions Brand 100% In-House CI
Adastra Holdings Ltd. Announces Executive Changes CI
Chart Adastra Holdings Ltd.
More charts
Adastra Holdings Ltd. is a Canada-based company, which is engaged in the supply and manufacturing of ethnobotanical and cannabis products. The Company serves medical markets and is engaged in therapeutic applications. The Company’s Phyto Extractions and Endgame Extracts brands distribute cannabis concentrate products through retailers at approximately 2,000 locations across Canada. As a Health Canada licensed facility, it specializes in extraction, distillation and manufacturing of a range of cannabis-derived products. It partners with healthcare professionals and practitioners within the regulated environment to create products suitable for the medical cannabis market. Its subsidiaries include Adastra Labs Holdings (2019) Ltd., Adastra Labs Inc., 1178562 B.C. Ltd., Adastra Brands Inc., Chemia Analytics Inc., 1225140 B.C. Ltd and 1204581 B.C. Ltd.
More about the company